

Immune therapy and targeted therapy in urothelial cancer

Poster Session 73

Monday, 27 March
14:00 - 15:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: Y. Allory, Creteil (FR)
A. Sato, Tokorozawa (JP)
A. Vlahou, Athens (GR)

Aims and objectives of this session

Not all patients respond to BCG therapy for urothelium tumours. Immunological mechanisms relevant to a possible improvement of BCG treatment will be discussed in this session. In addition, novel functions of growth factors which are highly expressed in bladder cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- 964 **Immune responsiveness to tuberculin in vitro may predict clinical outcome of intravesical BCG immunotherapy in bladder cancer**
By: [Jallad S.](#)¹, Thomas D.², Thomas P.³, Newport M.⁴, Kern F.⁴
Institutes:¹Brighton and Sussex Medical School, Dept. of Urology, Brighton, United Kingdom, ²Brighton and Sussex Medical School, Division of Medicine, Brighton, United Kingdom, ³Brighton and Sussex University Hospitals, Dept. of Urology, Brighton, United Kingdom, ⁴Brighton and Sussex University Hospitals, Division of Medicine, Brighton, United Kingdom
- 965 **Evaluation of pro- and anti-tumor effect induced by three colony-stimulating factors, G-CSF/GM-CSF/M-CSF using a human bladder cancer xenograft model: Is G-CSF a friend of cancer cells?**
By: [Hori S.](#), Miyake M., Tatsumi Y., Morizawa Y., Nakai Y., Goto D., Onishi K., Iida K., Onishi S., Tanaka N., Fujimoto K.
Institutes:Nara Medical University, Dept. of Urology, Kashihara, Japan
- *966 **Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells**
By: Ferreira-Teixeira M.², [Parada B.](#)¹, Paiva-Oliveira D.², Alves V.³, Sousa V.⁴, Chijioke O.⁵, Münz C.⁵, Reis F.⁶, Rodrigues-Santos P.⁷, Gomes C.⁶
Institutes:¹Coimbra University Hospital (CHUC), Urology and Renal Transplantation, Coimbra, Portugal, ²University of Coimbra - Faculty of Medicine, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, ³University of Coimbra - Faculty of Medicine, Institute of Immunology, Coimbra, Portugal, ⁴University of Coimbra - Faculty of Medicine, Institute of Anatomical and Molecular Pathology, Coimbra, Portugal, ⁵University of Zurich, Viral Immunobiology, Institute of Experimental Immunology, Zurich, Switzerland, ⁶University of Coimbra - Faculty of Medicine, Laboratory of Pharmacology and Experimental Therapeutics, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, ⁷University of Coimbra - Center For Neurosciences and Cell Biology (CNC), Immunology and Oncology Laboratory, Coimbra, Portugal
- 968 **IFN alpha modulates the response to BCG immunotherapy in bladder cancer patients with specific CTLA4 and CD28 single nucleotide polymorphisms**
By: [Esuvaranathan K.](#), Rahmat J., Tham S.M., Lim Y.K., Sng J.H., Raman L., Ma Z.M., Chan Y.H., Tsang W.C., Chiong E., Mahendran R.
Institutes:National University Singapore, Dept of Urology, Singapore, Singapore

- 969 **Inhibition of LIM-SH3 domain protein 1 (LASP1) augments the anti-cancer effect of cisplatin in bladder cancer**
By: Dejima T.¹, Takeuchi A.¹, Shiota M.¹, Black P.², Eto M.¹, Naito S.¹, Gleave M.², Ong C.²
Institutes:¹Kyusyu University, Dept. of Urology, Fukuoka, Japan, ²The Vancouver Prostate Centre, Dept. of Urologic Sciences, University of British Columbia, Vancouver, Canada
- 970 **HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy**
By: Shintani T., Daizumoto K., Fukawa T., Nakatsuji H., Fukumori T., Takahashi M., Kanayama H.
Institutes:Institute of Biomedical Sciences, Tokushima University Graduate School, Dept. of Urology, Tokushima, Japan
- 971 **The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine**
By: Isono M.¹, Sato A.¹, Asano T.¹, Okubo K.¹, Hoffmann M.², Schulz W.², Asano T.¹
Institutes:¹National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ²Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany
- 972 **T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+**
By: Hayashi T.¹, Oo H.², Jäger W.², Kobatake K.¹, Goriki A.², Seiler R.², Todenhöfer T.², Li N.², Fazli L.², Matsubara A.¹, Black P.²
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- 973 **Pathological significance and prognostic roles of c-Fes expression in bladder cancer differ depending on the grade**
By: Asai A., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Ohba K., Sakai H.
Institutes:Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan
- 974 **Reduced expressions of 4N1K-peptide derived from thrombospondin-2 is associated with malignant aggressiveness and prognosis in bladder cancer**
By: Mochizuki Y.¹, Miyata Y.¹, Yasuda T.¹, Nakamura Y.¹, Matsuo T.¹, Ohba K.¹, Furusato B.², Fukuoka J.², Sakai H.¹
Institutes:¹Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, ²Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan
- 975 **Compound A inhibits urothelial tumorigenesis via both glucocorticoid receptor and androgen receptor pathways**
By: Ide H.², Inoue S.³, Zheng Y.², Kashiwagi E.⁴, Kawahara T.⁵, Miyamoto H.¹
Institutes:¹University of Rochester, Dept. of Pathology, Urology and Oncology, Rochester, United States of America, ²Johns Hopkins University, Dept. of Pathology and Urology, Baltimore, United States of America, ³University of Rochester, Dept. of Pathology and Oncology, Rochester, United States of America, ⁴Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁵Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan
- 15:13 - 15:20 **New targets in urothelial cancer**
Y. Allory, Creteil (FR)